Progress and Challenges in the Use of MAP1LC3 as a Legitimate Marker for Measuring Dynamic Autophagy In Vivo

Srinivasa Reddy Bonam(Centre National de la Recherche Scientifique), Sylviane Muller(Centre National de la Recherche Scientifique)

Cells

May 25, 2020

10.3390/cells9051321

Cited by 44

Related Papers

Lysosomes as a therapeutic target

|Nature Reviews Drug Discovery|2019|751

Targeting the endo-lysosomal autophagy pathway to treat inflammatory bowel diseases

|Journal of Autoimmunity|2022|23

An Autophagy Modulator Peptide Prevents Lung Function Decrease and Corrects Established Inflammation in Murine Models of Airway Allergy

|Cells|2021|17

Long COVID-19 autoantibodies and their potential effect on fertility

|Frontiers in Immunology|2025|4